News & Analysis as of

Life Sciences Venture Capital Initial Public Offering (IPO)

WilmerHale

Royalty Financings and Similar Revenue Monetizations Surge in Difficult Life Sciences Fundraising Environment

WilmerHale on

Many biopharmaceutical companies are facing challenges raising cash through traditional equity markets. While venture investment activity saw a slight increase in the first half of 2024 as compared to the equivalent period in...more

Wilson Sonsini Goodrich & Rosati

[Event] Biotech Summit 2024 - October 9th - 10th, Boston, MA

Wilson Sonsini’s inaugural Biotech Summit will address topics of critical importance to Biotech and Biopharmaceutical companies, including early and late-stage venture financing, partnering strategies, current and future AI...more

Foley & Lardner LLP

HSBC Venture Healthcare Report: 1H 2024

Foley & Lardner LLP on

For a succinct analysis of 1H 2024 venture investment and exit activity in life sciences and health care, take a look at HSBC’s Venture Healthcare Report, Shake it off: HSBC Innovation Banking Analysis, 1H 2024. Lead author...more

Fenwick & West LLP

Silicon Alley: 15 Must-Know Facts about NY's Tech Community

Fenwick & West LLP on

As we countdown to NY Tech Week in just 15 days, here are 15 facts about the city's dynamic tech ecosystem....more

Troutman Pepper

Ready for the Biotech Bounce Back in 2024?

Troutman Pepper on

Heading into 2024, expectations for biotech venture capital (VC) and private equity (PE) investments were low following two lackluster years, but as we wrap up Q1, those expectations have been turned on their head after a...more

Goodwin

Healthcare Experts See Promising Signs of Rebound in M&A and IPO Activity

Goodwin on

In the second week of January, Goodwin and KPMG convened innovators, practitioners, regulators, and others for our annual symposium on the future of life sciences and healthcare. This marked the fifth year that Goodwin...more

Fenwick & West Life Sciences Group

In 2024, the Digital Health Revolution Continues

Digital health is showing signs of life despite financial markets that seem determined to bring some of 2023’s volatility into the new year. Stocks are up and down, and bond yields are climbing. Inflation is proving stubborn,...more

Fenwick & West Life Sciences Group

New Funding Cycle for Digital Health Begins on Cautious Note

For digital health startups, the first two months of this year were a welcome departure from 2022, when high inflation and other economic challenges caused investors to press on the brakes and proceed with caution....more

Allen Matkins

Life Sciences Real Estate Update - 3.21.23

Allen Matkins on

Despite a strong start last year, venture capital funding for life sciences totaled $35.8 billion in 2022, down 28% from 2021, according to Cushman & Wakefield (C&W). Initial public offering activity also fell 90% from $14.5...more

Orrick, Herrington & Sutcliffe LLP

Deal Flow 3.0: European Venture Capital Deal Term Review 2022

Foreword - Despite a shift to economic headwinds, investors injected more than $95B into the European tech market in 2022, the second-largest amount ever. To see how deal terms changed, Orrick developed new technologies and...more

Orrick, Herrington & Sutcliffe LLP

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q1 2023

This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2022 include: • Deal value reached $7.1 billion in Q4 across 392 deals, bringing the 2022 annual total to $38.0 billion...more

Wilson Sonsini Goodrich & Rosati

2022 Mid-Year Technology and Life Sciences "Non" IPO Report - Market Update and Playbook for Late-Stage Private Companies

Following a record-breaking year for initial public offerings (IPOs) in 2021, the U.S. capital markets screeched to a halt in 2022 with the lowest IPO activity levels seen in decades. This trend was observed across all...more

Orrick, Herrington & Sutcliffe LLP

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q3 2022

This report series examines quarterly trends in life sciences venture investment. Key findings for Q2 2022 include: • The industry generated $8.8 billion in deal value across 362 deals in Q2, a material decline from Q1, as...more

Fenwick & West Life Sciences Group

Digital Health Faced Headwinds in the First Quarter of 2022

Investors are understandably cautious this year as the Federal Reserve tightens monetary policies and financial markets erased the gains from the last 12 months. Public company investors in sectors with enticing upside—like...more

Orrick, Herrington & Sutcliffe LLP

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q2 2022

This edition of Orrick’s life sciences publication series breaks down the key drivers of venture investment in the life sciences industry during Q1 2022, which saw some disruptions following a record year in 2021. Key...more

Goodwin

European Life Sciences Deals Trends

Goodwin on

In Europe, life sciences deals increased over the last few years with strong acceleration in 2021. As a result, the market wonders whether this is just an uptick or rather a steady trend which will impact our market in the...more

White & Case LLP

European IPO activity proved strong, led by e-commerce and tech listings

White & Case LLP on

While IPO activity was robust throughout Europe, the Nordic region stood out - It was a blockbuster year for IPOs of European firms, following the global trend. In total, 476 European firms listed last year, excluding...more

Fenwick & West Life Sciences Group

Economic Conditions Changing, but Digital Health Still Strong

The digital health sector emerged as a juggernaut during the COVID-19 pandemic, with almost $15 billion invested in privately-held digital health companies in 2020 and nearly $30 billion invested last year, according to our...more

Fenwick & West Life Sciences Group

Rock Health Summit Brings Together Brightest Minds in Digital Health

In the technology sector, entrepreneurs are often told to “move fast and break things.” But breaking things is something that won’t work in healthcare, so, as an alternative, innovators may consider “moving fast and keeping...more

Orrick, Herrington & Sutcliffe LLP

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q3 2021

This edition of Orrick’s life sciences publication series reviews the key drivers of venture investment in the life sciences industry, which is proceeding at a record pace thus far in 2021. Key findings include: Investment...more

Fenwick & West Life Sciences Group

IPO Life Sciences Outlook: COVID-19 Vaccine Innovation Could Boost IPO Numbers to Another Record High

The life sciences sector will likely be one of the major drivers in what some analysts predict as the beginning of the largest economic expansion in recent history. ...more

Fenwick & West Life Sciences Group

Digital Health IPO Class of 2020: How Are They Performing Now?

In prior years, it was almost a foregone conclusion that promising digital health startups would be acquired by other companies before having the opportunity to debut on the public markets. However, that changed in 2019,...more

Orrick, Herrington & Sutcliffe LLP

Life Sciences Snapshot: A Quarterly Report on Financing Trends - Companies & Investors Navigate the Pandemic Era Q2 2020

In this edition of Orrick’s series of life sciences publications, we offer a market update drawing on a variety of PitchBook datasets depicting macro trends in financing across the market, as well as a spotlight on any trends...more

Fenwick & West Life Sciences Group

Digital Health Investments See Significant Uptick in Q1; Investors Consider COVID-19 Impacts in Coming Months

Despite the changes and uncertainty rippling across the entire venture-backed startup ecosystem, the digital health sector saw its best first quarter since analysts began tracking its performance more than a decade ago,...more

Fenwick & West Life Sciences Group

Key Takeaways from Fenwick’s 2019 Digital Health Investor Summit

Fenwick’s eighth annual Digital Health Investor Summit took place against the backdrop of strong and increasingly diverse investment markets, a focus on clinical validation of digital health tools, and a healthcare system...more

36 Results
 / 
View per page
Page: of 2

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide